Saro Arakelians, PharmD

Ten quiz questions to assess your knowledge on common treatments and counseling points for heart failure.

Cabozantinib (Cabometyx, Exelixis) is a kinase inhibitor approved for indications such as advanced renal cell carcinoma and hepatocellular carcinoma.

Brexucabtagene autoleucel (Tecartus, Kite Pharma) is a cell-based gene therapy for the treatment of adult patients with mantle cell lymphoma who have not responded to or who have relapsed following other treatments.

Ten quiz questions to assess your knowledge on common hypertension treatments.

Margetuximab-cmkb (Margenza) was approved in December 2020 in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens, at least one of which for metastatic disease.

Education and preparedness are essential for the treatment of this inherited disorder related to the musculosketal system.

Other options for Crohn disease and ulcerative colitis include biologics, corticosteroids, immunosuppressants, and vedolizumab.

Panzyga is indicated for the treatment of primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and chronic immune thrombocytopenia.

Sacituzumab govitecan is approved for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 more prior systemic therapies.

Lactitol (Pizensy) is an oral solution for treating chronic idiopathic constipation in adults.

Umbralisib was granted accelerated approval by the FDA for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.

Trilaciclib (Cosela) is indicated to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.

Antiviral medications, including Acyclovir, famciclovir, and valacyclovir, are effective if taken as soon as the diagnosis and can shorten the duration of the infection while improving symptoms.

Azacitidine (Onureg) was approved by the FDA in September 2020 as a maintenance therapy for acute myeloid leukemia.

The demand for drug treatments in Europe and North American has increased in recent years, as awareness of the bleeding disorder rises.

Xembify (immune globulin subcutaneous human–klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease in patients 2 years of age and older.

Pharmacists should educate themselves about the options available to help patients manage this bacterium that causes severe diarrhea and colitis.

Earlier this year, the FDA granted accelerated approval to tepotinib (Tepmetko, EMD Serono Inc) for the treatment of adults with metastatic non-small cell lung cancer who are harboring MET exon 14 skipping alterations.

The FDA recently approved the amyloid beta-directed antibody indicated for the treatment of the progressive disease.

Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses for the prevention of herpes zoster in adults aged 50 years and older.

Dupilumab is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins.

Risankizumab-rzaa (Skyrizi, AbbVie) is approved for the treatment of moderate-to-severe plaque psoriasis among adults who are candidates for systemic therapy or phototherapy.

Evinacumab-dgnb is the first FDA-approved treatment that binds to and blocks the function of angiopoietin-like 3, a protein that plays a key role in lipid metabolism.

It is important for health care providers to explain compliance to these regimens to patients, both from a clinical and cost perspective.

Cabenuva, the first long-acting injectable for the treatment of HIV, is a 2-drug copackaged product containing cabotegravir and rilpivirine.

Semaglutide (Ozempic) is a glucagon-like peptide 1 receptor agonist, approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

In March, the FDA approved dasiglucagon (Zegalogue) for the treatment of severe hypoglycemia in people with diabetes aged 6 years or older.

Ssatuximab (Sarclisa, Sanofi) is used in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

Treatment options include medications and recommendations to improve hygiene.

Melphalan flufenamide (Pepaxto; melflufen) is approved for use in combination with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma.